Extracellular Matrix Remodeling as a Mechanobiological Driver of Breast Cancer Aggressiveness: Comparative Oncology, Multi-Omics, and Artificial Intelligence Perspectives

The extracellular matrix (ECM) is increasingly recognized as an active regulator of breast cancer progression rather than a passive structural scaffold. This narrative review examines how ECM remodeling contributes to tumor aggressiveness through changes in matrix composition, collagen architecture, tissue stiffness, mechanotransduction, stromal permissiveness, immune and metabolic programs, invasion, metastasis and therapeutic response. A structured narrative search of literature published from 1981 to June 2026 was used to support this synthesis. Evidence from breast cancer studies indicates that collagens, fibronectin, laminins, proteoglycans, matricellular proteins, ECM-remodeling enzymes, and matrix-crosslinking pathways regulate integrin–FAK/Src, RhoA–ROCK, PI3K–AKT, MAPK, TGF-β/SMAD, Wnt/β-catenin, and YAP/TAZ signaling. Spontaneous canine mammary tumors are discussed as complementary comparative models that may preserve selected tumor–stroma–ECM interactions under naturally occurring disease conditions while requiring cautious interpretation due to species-specific biological and clinical differences. Proteomics, lipidomics, metabolomics, spatial omics, digital pathology, and artificial intelligence may support ECM-informed biomarker discovery and response prediction. However, translational application requires standardized pathology, reproducible assays, harmonized metadata, external validation, model interpretability, and clinically meaningful endpoints. Overall, ECM-informed comparative oncology is best viewed as a framework grounded in rigorous validation for identifying matrix-defined tumor phenotypes and prioritizing future biomarker and therapeutic strategies.